Gastric & Breast Cancer e-journal
DOI: 10.2122/gbc.2011.0172
NEWS & VIEWS
|
Improving Pancreatic Cancer Treatment with Combinatorial Chemotherapy Regimen and Erlotinib. |
Prof. Odysseas Zoras, M.D, PhD.
|
Affiliation: Professor Odysseas Zoras, Department of General Surgery, University Hospital of Heraklion, Medical School, University of Crete, Heraklion, Crete, Greece.
E-mail: ozoras@med.uoc.gr |
Since there is no abstract available we provide the first paragraph.
Chemotherapy with gemcitabine has been the standard treatment of patients with metastatic pancreatic cancer. A more aggressive combination chemotherapy regimen consisting of oxaliplatin, irinotecan, fluorouracil, and leucovorin (FOLFIRINOX) was proven more effective although at a higher toxicity than gemcitabine in a phase 3 trial published in the NEJM 2011 May issue. Targeting pancreatic cancer cells with EGFR signalling pathways-blocking drugs could provide a further survival improvement. Is erlotinib, a tyrosine kinase inhibitor, such a safe and effective drug?
http://www.gastricbreastcancer.com/grade_gmtmaster1675.asp
http://www.gastricbreastcancer.com/grade_deville.asp
(Citation: Gastric & Breast Cancer 2011; 10(3): 151-153)
|
|
| You can have an online full-text access and a PDF of this article: |
- Either purchase this paper for €33 EUR. Please, click here
|
|
- Or through one year subscription PayPal
|
|
Online
ISSN : 1109 - 7647
Print ISSN : 1109 - 7655
 We
subscribe to the HONcode principles. Verify
here.
please, read our policy about privacy
and confidentiality of information and transparency
of sponsorship
last
update: 28 June 2011 |
|
